“Novel Surgical Approach for Advanced HCC with PVTT after Tyrosine Kinase Inhibitors (TKIs) and PD-1 Inhibitors Combination Therapy Shows Favorable Long-term Survival and Portal Vein Patency”

https://pubmed.ncbi.nlm.nih.gov/38114938

The novel surgical approach for advanced HCC with portal vein tumor thrombus (PVTT) following combination therapy of tyrosine kinase inhibitors (TKIs) and programmed cell death protein 1 (PD-1) inhibitors shows favorable long-term survival and portal vein patency.